Benitec Biopharma Inc. 8-K

What Happened Benitec Biopharma Inc. (Nasdaq: BNTC) filed an 8-K on May 29, 2026 reporting that the Board appointed David Friedman as a director effective May 22, 2026. Friedman was named a Class III director with a term through the Company’s 2028 annual meeting. At the same time, Megan Boston, the Company’s chief financial officer and secretary, resigned from the Board effective May 22, 2026 but will continue in her CFO and secretary roles.

Key Details

• Appointment date: David Friedman appointed May 22, 2026; term ends at 2028 annual meeting.
• Equity grant: Friedman was granted options to purchase 35,000 shares under the Company’s 2020 Equity and Incentive Compensation Plan; grant date May 26, 2026.
• Exercise price: equal to the closing price of BNTC common stock on Nasdaq on May 26, 2026.
• Vesting: Options vest in full on the earlier of immediately prior to the next annual meeting or the first anniversary of the grant date.
• Compensation & protections: Friedman will receive the same non‑employee director compensation disclosed in the Company’s Oct 14, 2025 proxy and will sign the Company’s standard director indemnification agreement.
• No related-party transactions: The filing states there are no other transactions requiring disclosure under Item 404(a) of Regulation S‑K.
• Board change: Megan Boston rotated off the Board as part of a governance review; her resignation was not due to any dispute with the Company.

Why It Matters This 8-K signals a change in Benitec’s board composition and director compensation. The new director grant (35,000 options) is a routine recruiting/retention tool that could have modest dilution if exercised; the filing ties the exercise price to the market closing price on the grant date. Operational continuity is maintained because Megan Boston remains the Company’s CFO and secretary despite leaving the Board. Investors should note the governance update and the option grant as part of overall director-related expenses and potential future dilution disclosed in periodic filings.